Compugen Ltd.
NASDAQ:CGEN
2 (USD) • At close January 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Compugen Ltd. |
Symbool | CGEN |
Munteenheid | USD |
Prijs | 2 |
Beurswaarde | 179,072,800 |
Dividendpercentage | 0% |
52-weken bereik | 1.35 - 3.03 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Anat Cohen-Dayag Ph.D. |
Website | https://cgen.com |
An error occurred while fetching data.
Over Compugen Ltd.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)